Loading...

AnGes, Inc.

AMGXFPNK
Healthcare
Biotechnology
$0.36
$0.00(0.00%)
U.S. Market opens in 0h 43m

AnGes, Inc. Fundamental Analysis

AnGes, Inc. (AMGXF) shows moderate financial fundamentals with a PE ratio of -25.98, profit margin of -1.89%, and ROE of -44.53%. The company generates $0.5B in annual revenue with moderate year-over-year growth of 3.20%.

Key Strengths

Cash Position972.47%
PEG Ratio-0.00
Current Ratio1.96

Areas of Concern

ROE-44.53%
Operating Margin-6.18%
We analyze AMGXF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -153.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-153.2/100

We analyze AMGXF's fundamental strength across five key dimensions:

Efficiency Score

Weak

AMGXF struggles to generate sufficient returns from assets.

ROA > 10%
-22.09%

Valuation Score

Excellent

AMGXF trades at attractive valuation levels.

PE < 25
-25.98
PEG Ratio < 2
-0.00

Growth Score

Weak

AMGXF faces weak or negative growth trends.

Revenue Growth > 5%
3.20%
EPS Growth > 10%
-2.04%

Financial Health Score

Excellent

AMGXF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
1.96

Profitability Score

Weak

AMGXF struggles to sustain strong margins.

ROE > 15%
-4452.61%
Net Margin ≥ 15%
-1.89%
Positive Free Cash Flow
No

Key Financial Metrics

Is AMGXF Expensive or Cheap?

P/E Ratio

AMGXF trades at -25.98 times earnings. This suggests potential undervaluation.

-25.98

PEG Ratio

When adjusting for growth, AMGXF's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values AnGes, Inc. at 10.08 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

10.08

EV/EBITDA

Enterprise value stands at -6.41 times EBITDA. This is generally considered low.

-6.41

How Well Does AMGXF Make Money?

Net Profit Margin

For every $100 in sales, AnGes, Inc. keeps $-1.89 as profit after all expenses.

-1.89%

Operating Margin

Core operations generate -6.18 in profit for every $100 in revenue, before interest and taxes.

-6.18%

ROE

Management delivers $-44.53 in profit for every $100 of shareholder equity.

-44.53%

ROA

AnGes, Inc. generates $-22.09 in profit for every $100 in assets, demonstrating efficient asset deployment.

-22.09%

Following the Money - Real Cash Generation

Operating Cash Flow

AnGes, Inc. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

AnGes, Inc. generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

AMGXF converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-25.98

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

10.08

vs 25 benchmark

P/S Ratio

Price to sales ratio

36.07

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.96

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.45

vs 25 benchmark

ROA

Return on assets percentage

-0.22

vs 25 benchmark

ROCE

Return on capital employed

-1.24

vs 25 benchmark

How AMGXF Stacks Against Its Sector Peers

MetricAMGXF ValueSector AveragePerformance
P/E Ratio-25.9829.06 Better (Cheaper)
ROE-44.53%646.00% Weak
Net Margin-188.68%-44088.00% (disorted) Weak
Debt/Equity0.020.33 Strong (Low Leverage)
Current Ratio1.964.49 Neutral
ROA-22.09%-15444.00% (disorted) Weak

AMGXF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews AnGes, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-12.42%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-233.76%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-35.01%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ